NASH – February 2021 NASH – February 2021 Target RWE announced results on weight loss from an ongoing NASH longitudinal observational study 02 Feb 2021 Target RWE TARGET-NASH is a 5-year longitudinal observational study of patients being managed for NAFL […]
NASH – January 2021 NASH – January 2021 FDA cleared IND for TERN-501 Phase 1 trial for the treatment of NASH 19 Jan 2021 Terns Pharmaceuticals – TERN-501 (THR-β agonist, Phase 1); TERN-101 (FXR agonist, Phase 2a) TERN-501 will be […]
NASH – January 2021 NASH – January 2021 Hanmi Pharma expanded its LAPSTriple Agonist, HM15211 into Phase 2 for the treatment of NASH and other diseases 18 Jan 2021 Hanmi Pharma – HM15211 (LAPSTriple Agonist, Phase 2) In recent clinical […]
NASH – January 2021 NASH – January 2021 Lipocine presented encouraging Phase 2 LiFT study results of LPCN 1144 12 Jan 2021 Lipocine – LPCN 1144 (Androgen receptor agonist, Phase 2) The Phase 2 LiFT trial is a randomized, double-blind, […]
NASH – January 2021 NASH – January 2021 Inventiva announced design of Phase 3 clinical trial with lanifibranor in NASH 06 Jan 2021 Inventiva – Lanifibranor (pan-PPAR agonist, Phase 3) Inventiva planned a single global Phase 3 (NATIVE3) trial evaluating […]
